NCT04387227

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, enrolled Phase 2 Last updated 18 September 2025

What this trial tests

Phase 2 trial testing Carboplatin in Recurrent Fallopian Tube Carcinoma in 22 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 March 2021

Primary endpoint
12 September 2025

1 June 2026

Quick facts

Lead sponsor	University of Washington
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	18 March 2021
Primary completion	12 September 2025
Estimated completion	1 June 2026
Sites	1 location across United States

Drugs / interventions tested

• Carboplatin (Carboplatin) — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →
• Computed Tomography
• Magnetic Resonance Imaging
• Biospecimen Collection — full drug profile →

Conditions studied

• Recurrent Fallopian Tube Carcinoma — all drugs for Recurrent Fallopian Tube Carcinoma →
• Recurrent Ovarian Carcinoma — all drugs for Recurrent Ovarian Carcinoma →
• Recurrent Primary Peritoneal Carcinoma — all drugs for Recurrent Primary Peritoneal Carcinoma →

Sponsor

University of Washington

Who can join

18 and older, female only, with Recurrent Fallopian Tube Carcinoma or Recurrent Ovarian Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial investigates how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together with carboplatin may work better in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
   Yang Y, Yang Y, Yang J, Zhao X, et al · · 2020 · cited 168× · PMID 32850861 · DOI 10.3389/fcell.2020.00758
2. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
   Tavares V, Marques IS, Melo IG, Assis J, et al · · 2024 · cited 85× · PMID 38339123 · DOI 10.3390/ijms25031845
3. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
   Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. · · 2021 · cited 60× · PMID 34503248 · DOI 10.3390/cancers13174438
4. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
   Pawłowska A, Rekowska A, Kuryło W, Pańczyszyn A, et al · · 2023 · cited 41× · PMID 37446039 · DOI 10.3390/ijms241310859
5. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
   Ornella MSC, Badrinath N, Kim KA, Kim JH, et al · · 2023 · cited 24× · PMID 37190310 · DOI 10.3390/cancers15082383
6. Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer.
   Huang X, Li XY, Shan WL, Chen Y, et al · · 2023 · cited 14× · PMID 37033645 · DOI 10.3389/fphar.2023.1131342